Last update May 20, 2024
Likely Compatibility
Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.
Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.
Thank you for helping to protect and promote breastfeeding.
1-(4-Amino-6,7-dimethoxyquinazolin-2-yl)-4-(tetrahydro-2-furoyl)piperazine hydrochloride dihydrate; 6,7-Dimethoxy-2-[4-(tetrahydrofuran-2-carbonyl)piperazin-1-yl]quinazolin-4-ylamine hydrochloride dihydrate is Terazosin Hydrochloride in Chemical name.
Is written in other languages:1-(4-Amino-6,7-dimethoxyquinazolin-2-yl)-4-(tetrahydro-2-furoyl)piperazine hydrochloride dihydrate; 6,7-Dimethoxy-2-[4-(tetrahydrofuran-2-carbonyl)piperazin-1-yl]quinazolin-4-ylamine hydrochloride dihydrate belongs to these groups or families:
Main tradenames from several countries containing 1-(4-Amino-6,7-dimethoxyquinazolin-2-yl)-4-(tetrahydro-2-furoyl)piperazine hydrochloride dihydrate; 6,7-Dimethoxy-2-[4-(tetrahydrofuran-2-carbonyl)piperazin-1-yl]quinazolin-4-ylamine hydrochloride dihydrate in its composition:
Variable | Value | Unit |
---|---|---|
Oral Bioavail. | 90 | % |
Molecular weight | 460 | daltons |
Protein Binding | 94 | % |
VD | 0.35 - 0.43 | l/Kg |
pKa | 7.24 | - |
Tmax | 1 - 2 | hours |
T½ | 9 - 12 | hours |
Write us at elactancia.org@gmail.com
e-lactancia is a resource recommended by Academy of Breastfeeding Medicine - 2015 of United States of America
Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM
Alpha-1 adrenergic blocker used in the treatment of arterial hypertension and obstructive symptoms derived from benign prostatic hypertrophy. Oral administration once daily.
At the time of the last update, we found no published data on its excretion in breast milk.
Its pharmacokinetic data (moderately high molecular weight, very high percentage of protein binding, and high volume of distribution) make it unlikely that significant quantities will pass into milk.
Pending further published data on this drug in relation to breastfeeding, safer known alternatives may be preferable (Anderson 2018, Malachias 2016), especially during the neonatal period and in case of prematurity.